Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

There’s no question about the popularity of GLP-1 weight loss drugs like Ozempic and Wegovy, but some doctors are worried the ...

New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

While furosemide and other diuretics can help with symptoms, the drugs that have had a very significant impact on the ...

This article is part of a special series investigating the GLP-1 agonist boom. Read more here. A growing number of studies show that semaglutide seems to have many beneficial effects in addition ...

This article is part of a special series investigating the GLP-1 agonist boom. Read more here. Among the comments, however, you will frequently find reports of other – wholly unexpected ...

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

and GLP-1 agonists such as semaglutide (in people with both HFpEF and obesity). These drugs help people lose weight and have also been shown to reduce hospitalization for heart failure.

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...